1. Market Research
  2. > Biotechnology Market Trends
  3. > Planet Biotechnology Inc. - Product Pipeline Review - 2014

Planet Biotechnology Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 25 pages

Planet Biotechnology Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Planet Biotechnology Inc. - Product Pipeline Review - 2014’, provides an overview of the Planet Biotechnology Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Planet Biotechnology Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Planet Biotechnology Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Planet Biotechnology Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Planet Biotechnology Inc.’s pipeline products

Reasons to buy

- Evaluate Planet Biotechnology Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Planet Biotechnology Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Planet Biotechnology Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Planet Biotechnology Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Planet Biotechnology Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Planet Biotechnology Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Planet Biotechnology Inc. - Product Pipeline Review - 2014
Table of Contents

Planet Biotechnology Inc. Snapshot 4
Planet Biotechnology Inc. Overview 4
Key Information 4
Key Facts 4
Planet Biotechnology Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Planet Biotechnology Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Planet Biotechnology Inc. - Pipeline Products Glance 9
Planet Biotechnology Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Planet Biotechnology Inc. - Drug Profiles 11
PBI-220 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Recombinant Peptides to Inhibit Botulinum Toxin for Botulism 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
SARS Vaccine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Recombinant Protein for Cancer 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Planet Biotechnology Inc. - Pipeline Analysis 19
Planet Biotechnology Inc. - Pipeline Products by Target 19
Planet Biotechnology Inc. - Pipeline Products by Molecule Type 20
Planet Biotechnology Inc. - Pipeline Products by Mechanism of Action 21
Planet Biotechnology Inc. - Dormant Projects 22
Planet Biotechnology Inc. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables

Planet Biotechnology Inc., Key Information 4
Planet Biotechnology Inc., Key Facts 4
Planet Biotechnology Inc. - Pipeline by Indication, 2014 6
Planet Biotechnology Inc. - Pipeline by Stage of Development, 2014 7
Planet Biotechnology Inc. - Monotherapy Products in Pipeline, 2014 8
Planet Biotechnology Inc. - Preclinical, 2014 9
Planet Biotechnology Inc. - Discovery, 2014 10
Planet Biotechnology Inc. - Pipeline by Target, 2014 19
Planet Biotechnology Inc. - Pipeline by Molecule Type, 2014 20
Planet Biotechnology Inc. - Pipeline Products by Mechanism of Action, 2014 21
Planet Biotechnology Inc. - Dormant Developmental Projects,2014 22

List of Figures

Planet Biotechnology Inc. - Pipeline by Top 10 Indication, 2014 6
Planet Biotechnology Inc. - Pipeline by Stage of Development, 2014 7
Planet Biotechnology Inc. - Monotherapy Products in Pipeline, 2014 8
Planet Biotechnology Inc. - Pipeline by Top 10 Target, 2014 19
Planet Biotechnology Inc. - Pipeline by Top 10 Molecule Type, 2014 20
Planet Biotechnology Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.